Literature DB >> 24156266

Pathological reorganization of NMDA receptors subunits and postsynaptic protein PSD-95 distribution in Alzheimer's disease.

Genevieve Leuba, Andre Vernay, Rudolf Kraftsik, Eric Tardif, Beat Michel Riederer, Armand Savioz1.   

Abstract

In Alzheimer's disease (AD), synaptic alterations play a major role and are often correlated with cognitive changes. In order to better understand synaptic modifications, we compared alterations in NMDA receptors and postsynaptic protein PSD-95 expression in the entorhinal cortex (EC) and frontal cortex (FC; area 9) of AD and control brains. We combined immunohistochemical and image analysis methods to quantify on consecutive sections the distribution of PSD-95 and NMDA receptors GluN1, GluN2A and GluN2B in EC and FC from 25 AD and control cases. The density of stained receptors was analyzed using multivariate statistical methods to assess the effect of neurodegeneration. In both regions, the number of neuronal profiles immunostained for GluN1 receptors subunit and PSD-95 protein was significantly increased in AD compared to controls (3-6 fold), while the number of neuronal profiles stained for GluN2A and GluN2B receptors subunits was on the contrary decreased (3-4 fold). The increase in marked neuronal profiles was more prominent in a cortical band corresponding to layers 3 to 5 with large pyramidal cells. Neurons positive for GluN1 or PSD-95 staining were often found in the same localization on consecutive sections and they were also reactive for the anti-tau antibody AD2, indicating a neurodegenerative process. Differences in the density of immunoreactive puncta representing neuropile were not statistically significant. Altogether these data indicate that GluN1 and PSD-95 accumulate in the neuronal perikarya, but this is not the case for GluN2A and GluN2B, while the neuropile compartment is less subject to modifications. Thus, important variations in the pattern of distribution of the NMDA receptors subunits and PSD-95 represent a marker in AD and by impairing the neuronal network, contribute to functional deterioration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24156266     DOI: 10.2174/15672050113106660170

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  17 in total

Review 1.  Estrogenic Endocrine Disrupting Chemicals Influencing NRF1 Regulated Gene Networks in the Development of Complex Human Brain Diseases.

Authors:  Mark Preciados; Changwon Yoo; Deodutta Roy
Journal:  Int J Mol Sci       Date:  2016-12-13       Impact factor: 5.923

2.  p120-catenin is necessary for neuroprotection induced by CDK5 silencing in models of Alzheimer's disease.

Authors:  Alejandro Uribe-Arias; Rafael Andrés Posada-Duque; Christian González-Billault; Andrés Villegas; Francisco Lopera; Gloria Patricia Cardona-Gómez
Journal:  J Neurochem       Date:  2016-07-05       Impact factor: 5.372

3.  Bayesian integrative analysis of epigenomic and transcriptomic data identifies Alzheimer's disease candidate genes and networks.

Authors:  Hans-Ulrich Klein; Martin Schäfer; David A Bennett; Holger Schwender; Philip L De Jager
Journal:  PLoS Comput Biol       Date:  2020-04-07       Impact factor: 4.475

4.  p35 and Rac1 underlie the neuroprotection and cognitive improvement induced by CDK5 silencing.

Authors:  Rafael Andres Posada-Duque; Alejandro López-Tobón; Diego Piedrahita; Christian González-Billault; Gloria Patricia Cardona-Gomez
Journal:  J Neurochem       Date:  2015-05-04       Impact factor: 5.372

5.  A Novel Aβ B-Cell Epitope Vaccine (rCV01) for Alzheimer's Disease Improved Synaptic and Cognitive Functions in 3 × Tg-AD Mice.

Authors:  Yun-Zhou Yu; Si Liu; Hai-Chao Wang; DanYang Shi; Qing Xu; Xiao-Wei Zhou; Zhi-Wei Sun; Pei-Tang Huang
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-05       Impact factor: 4.147

6.  NeuroRDF: semantic integration of highly curated data to prioritize biomarker candidates in Alzheimer's disease.

Authors:  Anandhi Iyappan; Shweta Bagewadi Kawalia; Tamara Raschka; Martin Hofmann-Apitius; Philipp Senger
Journal:  J Biomed Semantics       Date:  2016-07-08

7.  RGS2 expression predicts amyloid-β sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining.

Authors:  A Hadar; E Milanesi; A Squassina; P Niola; C Chillotti; M Pasmanik-Chor; O Yaron; P Martásek; M Rehavi; D Weissglas-Volkov; N Shomron; I Gozes; D Gurwitz
Journal:  Transl Psychiatry       Date:  2016-10-04       Impact factor: 6.222

Review 8.  Emerging Synaptic Molecules as Candidates in the Etiology of Neurological Disorders.

Authors:  Viviana I Torres; Daniela Vallejo; Nibaldo C Inestrosa
Journal:  Neural Plast       Date:  2017-02-26       Impact factor: 3.599

9.  A novel recombinant 6Aβ15-THc-C chimeric vaccine (rCV02) mitigates Alzheimer's disease-like pathology, cognitive decline and synaptic loss in aged 3 × Tg-AD mice.

Authors:  Yun-Zhou Yu; Si Liu; Hai-Chao Wang; Dan-Yang Shi; Qing Xu; Xiao-Wei Zhou; Zhi-Wei Sun; Pei-Tang Huang
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

10.  Protective effects of Dendrobium nobile Lindl. alkaloids on amyloid beta (25-35)-induced neuronal injury.

Authors:  Wei Zhang; Qin Wu; Yan-Liu Lu; Qi-Hai Gong; Feng Zhang; Jing-Shan Shi
Journal:  Neural Regen Res       Date:  2017-07       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.